English | 简体中文 | 繁體中文 | 한국어 | 日本語
Wednesday, 24 April 2019, 9:36 JST
Share:
    

Source: Eisai
Eisai Selected as Competitive ICT Strategy Company for 2019
Recognized for Taking on Challenge of Transformation to New Business Models by Integrating Management and Ict Strategies

TOKYO, Apr 24, 2019 - (JCN Newswire) - Eisai Co., Ltd. has been selected by the Ministry of Economy, Trade and Industry (METI) and the Tokyo Stock Exchange (TSE) as a Competitive IT Strategy Company 2019 as a company that is engaged in the strategic utilization of IT. This marks the first time a pharmaceutical company has been selected as a Competitive IT Strategy Company.

The aim of the Competitive IT Strategy Company program is to introduce companies as attractive companies to investors who emphasize improving corporate value over the mid- to long-term and to promote companies? Competitive IT Strategies. Under the program, METI and TSE jointly select and announce companies who are engaged in the strategic use of IT.

Companies are assessed according to five areas: "Utilization of IT to increase corporate value in terms of management policies and plans," "Strategic utilization of IT to increase corporate value," "Systems and personnel for promoting the Competitive IT Strategy," "Fundamental initiatives supporting the Competitive IT Strategy," as well as "Initiatives focused on evaluating and improving IT investment to increase corporate value."

In this fifth iteration of the program, 29 companies were selected from among approximately 3,600 publicly-listed Japanese companies.

Under the ICT Driven Innovation strategy in the medium-term business plan EWAY2025, Eisai is promoting various initiatives using IT for the enhancement of corporate value in order to realize a digital transformation that integrates management and ICT strategies. Eisai?s recognition as a Competitive IT Strategy Company highlighted its utilization of IT to contribute to the enhancement of corporate value as well as its application of new digital technologies.

Eisai's corporate philosophy is to give first thought to patients and their families, and increase the benefits that health care provides as well as address diverse healthcare needs worldwide. Based on this human health care (hhc) philosophy, Eisai will take this opportunity to continue employing competitive IT strategy to further improve productivity and create innovation, and strive to further enhance corporate value.

Contact:
Public Relations Department,
Eisai Co., Ltd.
+81-(0)3-3817-5120 


Topic: Press release summary
Source: Eisai

Sectors: BioTech
https://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2026 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.

 

Eisai Related News
Monday, 26 January 2026, 11:37 JST
FDA Accepts LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease under Priority Review
2026年1月26日 8時40分 JST
エーザイとバイオジェン、抗 Aβ抗体レカネマブの皮下注射製剤「LEQEMBI(R) IQLIK(TM)」について、早期アルツハイマー病に対する初期療法からの投与を可能とする生物製剤承認一部変更申請が米国 FDA に受理され、優先審査に指定
Wednesday, 21 January 2026, 16:44 JST
Eisai Listed as a Global 100 Most Sustainable Corporation for the Tenth Time
Tuesday, 13 January 2026, 9:50 JST
Eisai and Nuvation Bio Enter into Exclusive Licensing Agreement for Taletrectinib in Europe and Additional Countries Outside the U.S., China and Japan
Tuesday, 6 January 2026, 10:43 JST
Biologics License Application for Subcutaneous Formulation of "LEQEMBI(R)" (lecanemab) for the Treatment of Early Alzheimer's Disease Accepted in China
More news >>
Copyright © 2026 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575